Lenalidomide

Overview

Lenalidomide is a derivative of thalidomide with immunomodulatory and antiangiogenic properties. It is used in the treatment of various types of cancer, particularly multiple myeloma, and certain hematological disorders.

API suppliers (17)

Suppliers of Lenalidomide evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

• Cipla USA, Inc.USA2 active DMF
• Zydus Lifesciences LimitedIndia1 active DMF GMP on record
• Reliance Life Sciences Pvt. Ltd.India1 active DMF GMP on record
• DR REDDYS LABORATORIES LTD1 active DMF GMP on record
• MATRIX PHARMACORP PRIVATE LTDIndia1 active DMF
• CHANGZHOU PHARMACEUTICAL FACTORYChina1 active DMF GMP on record
• Sun Pharmaceutical Industries LimitedIndia1 active DMF GMP on record
• MSN Laboratories Private LimitedIndia1 active DMF GMP on record
• SHILPA PHARMA LIFESCIENCES LTDIndia1 active DMF
• SynthonNetherlands1 active DMF GMP on record
• Biocon LimitedIndia1 active DMF
• Kyongbo Pharmaceutical Co., Ltd.South1 active DMF
• Deva Holding As1 active DMF GMP on record
• VERANOVA LPUnited Kingdom1 active DMF
• APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
• VALARY LAB PRIVATE LIMITEDIndia1 active DMF GMP on record
• MYLAN LABORATORIES LTD GMP on record

Patent & exclusivity (US)

Per the FDA Orange Book (113 approved US products), the latest listed US patent on Lenalidomide expires 8 Mar 2028 and exclusivity 28 May 2026. Generic API sourcing typically opens up once these lapse.

Therapeutic areas